Approximately 10.5% of medicines in low and middle income countries including India are sub-standard and falsified, said WHO in this report.

This report has grown out of the work of the GSMS, which provides national regulatory authorities with an interconnected network. This allows them, for the first time, to cross-reference reports of suspect products with those reported from other regions by searching the WHO database and accessing photograph libraries of confirmed substandard and falsified products.